- Conditions
- Urinary Tract Infection, Acute Pyelonephritis
- Interventions
- TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion, Dummy Tablets
- Drug
- Lead sponsor
- Spero Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,690 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Infections, Urinary Tract
- Interventions
- GSK2251052, imipenem-cilastatin, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Council Bluffs, Iowa • Topeka, Kansas + 1 more
- Conditions
- Bacterial Infections
- Interventions
- XNW4107
- Drug
- Lead sponsor
- Evopoint Biosciences Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Suspected or Documented Gram-negative Bacterial Infection
- Interventions
- IMI/REL FDC
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 1 Day to 17 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Orange, California • San Diego, California + 5 more
- Conditions
- Acinetobacter Baumannii-calcoaceticus Complex, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Colistin Resistant ABC
- Interventions
- Sulbactam, Durlobactam, Colistin, Imipenem/Cilastatin 500 mg/500 mg
- Drug
- Lead sponsor
- Entasis Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Shreveport, Louisiana • Cincinnati, Ohio + 2 more
- Conditions
- Suspected or Documented Gram-negative Bacterial Infection
- Interventions
- IMI/REL, Active Control, Oral Switch
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Long Beach, California • San Diego, California + 5 more
- Conditions
- Bacterial Infections
- Interventions
- XNW4107, Imipenem/Cilastatin
- Drug
- Lead sponsor
- Evopoint Biosciences Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona